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Purpose: The aim of this study was to explore the clinical and pathological characteristics of pure 
mucinous breast carcinoma (PMBC) according to internal echogenicity on ultrasonography (US). 
Methods: Thirty-three patients with PMBC diagnosed at surgery were included in this study. 
Cases of PMBC were classified according to internal echogenicity on US. The imaging features on 
magnetic resonance (MR) imaging and clinicohistopathological characteristics were compared 
between the hypoechogenic and the isoechogenic to hyperechogenic groups.
Results: Eleven cases of PMBC (33.3%) exhibited hypoechogenicity on US, while 22 cases 
(66.7%) exhibited isoechogenicity or hyperechogenicity. Of the isoechogenic to hyperechogenic 
PMBCs, 95.5% showed a high signal on T2-weighted images, which was a significantly greater 
percentage than was observed for the hypoechogenic group (54.5%) (P=0.010). Of the 
hypoechogenic PMBCs, 63.6% showed a washout pattern in the delayed phase, which was 
substantially more than the result of 23.8% observed for the isoechogenic to hyperechogenic 
PMBCs (P=0.053). 
Conclusion: PMBCs with isoechogenicity or hyperechogenicity were more likely to show a high 
signal intensity on T2-weighted images than hypoechogenic PMBCs. However, other MR imaging 
and clinicohistopathological characteristics were not significantly different between the two 
groups. 
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Introduction
Mucinous carcinoma of the breast is a rare subtype of invasive ductal carcinoma with an incidence 
of 1%-7%, and it usually occurs in women over 60 years of age [1,2]. Mucinous carcinoma can 
be classified into two types: pure mucinous carcinoma, which has a mucinous component of more 
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than 90%; and mixed mucinous carcinoma, which has a mucinous 
component greater than 50% but less than 90%, admixed with 
areas with distinct architectural patterns, usually of invasive 
carcinoma of no special type [3,4]. Pure mucinous breast carcinoma 
(PMBC) is less aggressive and is less likely to lead to lymph node 
metastasis than mixed mucinous carcinoma [1,5-7]. 
PMBC commonly presents as a well-circumscribed mass on 
mammography [2,8]. On ultrasonography (US), 64%-86% of 
PMBCs show isoechogenicity [2,9,10]. On magnetic resonance (MR) 
imaging, PMBC shows a high signal intensity on T2-weighted or 
short tau inversion recovery (STIR) T2-weighted images [11-14], 
and no restricted diffusion with high apparent diffusion coefficient 
(ADC) values on diffusion-weighted images [14,15]. 
To our knowledge, no study has evaluated the clinical and 
pathological characteristics of PMBC according to echogenicity on 
US. Therefore, the demographic, MR imaging-related, and histologic 
characteristics of PMBC were investigated according to internal 
echogenicity on US. 
Materials and Methods
The Institutional Review Board of our institution approved this 
retrospective study and waived the requirement for informed 
consent. 
Study Population
From March 2012 to February 2015, 57 patients at our institution 
were diagnosed with mucinous carcinoma in the breast, of whom 
48 had PMBC. Of these patients, the following were excluded: 
seven patients who underwent MR imaging after excision, five 
who underwent MR imaging using different protocols, two who 
underwent MR imaging at another hospital, and one patient who 
was male. Ultimately, 33 female patients who underwent breast MR 
imaging were included. The median age of the patients was 47 years 
(range, 31 to 79 years). The median lesion size was 17 mm (range, 5 
to 37 mm) on MR imaging.
Mammography and US 
Mammography was performed using the Lorad/Hologic Selenia full-
field digital mammography system (Lorad/Hologic, Danbury, CT, 
USA) and the General Electric Senographe digital mammography 
system (GE Medical Systems, Milwaukee, WI, USA). Craniocaudal 
and mediolateral oblique views were routinely obtained. Additional 
views were obtained when needed. Breast density was classified 
according to the American College of Radiology Breast Imaging 
Reporting and Data System (ACR BI-RADS) [16,17] and was 
recorded in the original radiological reports. Mammographic density 
was categorized as fatty (scores of A or B and 1 or 2) or dense (scores 
of C or D and 3 or 4). 
Breast US examinations were performed by 11 board-certified 
radiologists with 1 to 21 years of experience in breast imaging using 
US machines (iU22, Philips-Advanced Technology Laboratories, 
Bothell, WA, USA; Logic 9, GE Medical Systems) and 5-12- or 
7-12-MHz linear array transducers. The echogenicity of the tumors 
on US was analyzed according to the ACR BI-RADS criteria [16,17]. 
The internal echo patterns of the tumors were retrospectively 
reanalyzed by one radiologist with 13 years of experience in breast 
imaging (H.J.M.). The tumors were classified into two categories 
according to echogenicity in comparison to the echogenicity of the 
premammary fat tissue, resulting in a hypoechogenic group and an 
isoechogenic to hyperechogenic group [17]. 
MR Imaging Technique
MR imaging of the breast was performed with a 3.0-T MR 
system (Discovery MR750w, GE Healthcare, Milwaukee, WI, USA). 
Commercially dedicated phased array breast coils were used in 
all cases with the patient in the prone position. Axial T2-weighted 
images were acquired using a fast spin-echo sequence (repetition 
time [TR]/echo time [TE], 4,187 msec/102 msec; field of view [FOV], 
320×320 mm; matrix, 320×256 pixels; section thickness, 3 mm), 
and axial STIR T2-weighted images (TR/TE, 5,000 msec/70 msec; 
inversion time, 200 msec) were acquired. After obtaining diffusion-
weighted MR images with a 2-dimensional spin-echo echo-planar 
imaging sequence, axial T1-weighted dynamic contrast-enhanced 
MR images of the entire breast were acquired before and 5 times 
after the intravenous administration of gadopentetate dimeglumine 
(Dotarem, Guerbet, Paris, France; Magnevist, Berlex Laboratories, 
Wayne, NJ, USA; Gaudiest, Bayer Schering Pharma, Berlin, Germany) 
using 0.2 mL/kg at a rate of 2.0 mL/sec (VIBRAT-Flex Din. imaging, 
GE Healthcare; matrix, 280×512 pixels; flip angle, 12°; FOV, 
320×320 mm; section thickness, 3 mm, no intersection gap). Thus, 
six postcontrast images were acquired at approximately 0, 63, 126, 
189, 252, and 315 seconds after the intravenous administration of 
contrast, and temporal samplings of the center of k-space for the 
post-contrast series were obtained at approximately 32, 95, 158, 
221, 284, and 347 seconds. Subtraction images were generated. 
The signal intensity on T2-weighted MR images and STIR T2-
weighted images was visually classified as low, isointense, or high 
relative to the surrounding mammary parenchymal tissue. The 
degree of internal enhancement was classified as low, isoenhanced, 
or high, relative to the surrounding enhancing parenchymal 
tissues on the second subtraction images. Lesion size, dynamic 
enhancement pattern, peak enhancement, and ADC values were 
measured using a commercially available computer-aided evaluation 
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system (CADstream, Confirma, Inc., Kirkland, WA, USA). Dynamic 
enhancement patterns were categorized as slow, medium, or rapid 
for the early phase and washout, persistent, or plateau for the 
delayed phase. To measure ADC values, the region of interest was 
manually drawn on the ADC map (b value=0, 600 sec/mm²) 3 times. 
The mean ADC value was calculated.
Histopathologic Analysis 
Pathologic characteristics such as pathologic lesion size, infiltrative 
or expanding tumor margins, nuclear and histologic grades, the 
presence or absence of lymph node metastases, and lymphovascular 
invasion were compared between the two groups. The groups were 
also compared according to the presence of estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (HER2). ER and PR assays were considered positive if 
at least 1% of tumor nuclei were positive. HER2 positivity was 
defined as HER2 immunochemistry results of 3+ or HER2 gene 
amplification by silver-enhanced in situ hybridization analysis [18,19]. 
Ki-67 proliferation of <14% was defined as negative and ≥14% as 
positive [20].
Data and Statistical Analysis 
PMBCs were classified according to internal echogenicity on US, 
with the hypoechogenic group including PMBCs that exhibited 
hypoechogenicity and the isoechogenic to hyperechogenic group 
including PMBCs that exhibited isoechogenicity or hyperechogenicity. 
Table 1. Imaging characteristics of mucinous carcinoma according to echogenicity on ultrasonography
US echogenicity Total Hypoechogenic (n=11)
Isoechogenic to hyperechogenic 
 (n=22)
P-value
Age, median (range, yr) 47 (31-79) 58 (38-79) 46 (31-69) 0.069
Symptom >0.990
Negative 10 (30.3) 3 (27.3) 7 (31.8)
Palpable 23 (69.7) 8 (72.7) 15 (68.2)
Mammographic densitya) 0.121
A, B 9 (27.3) 5 (45.5) 4 (18.2)
C, D 24 (72.7) 6 (54.5) 18 (81.8)
MR imaging features
Lesion size, median (range, mm) 17 (5-37) 16 (8-34) 18 (5-37) 0.849
Signal intensity on T2-weighted images 0.010
Isointense 6 (18.2) 5 (45.5) 1 (4.5)
High 27 (81.8) 6 (54.5) 21 (95.5)
Signal intensity on STIR T2-weighted images 0.097
Isointense 4 (12.1) 3 (27.3) 1 (4.5)
High 29 (87.9) 8 (72.7) 21 (95.5)
Internal enhancement 0.219
Low 3 (9.1) 0 ( 3 (13.6)
Isoenhancement 18 (54.5) 5 (45.5) 13 (59.1)
High 12 (36.4) 6 (54.5) 6 (27.3)
Early enhancement 0.593b)
Medium 4 (12.5) 2 (18.2) 2 (9.5)
Rapid 28 (87.5) 9 (81.8) 19 (90.5)
Delay enhancement 0.053b)
Persistent or plateau 20 (62.5) 4 (36.4) 16 (76.2)
Washout 12 (37.5) 7 (63.6) 5 (23.8)  
Peak enhancement, median (range, %) - 203 (84-376) 215 (66-549) 0.166
ADC value, mean (range) - 1.90 (1.59-1.95) 1.92 (1.17-2.44) 0.133
Values are presented as number (%) unless otherwise indicated.
US, ultrasonography; MR, magnetic resonance; STIR, short tau inversion recovery; ADC, apparent diffusion coefficient.
a)A, almost entirely fatty; B, scattered fibroglandular tissue; C, heterogeneously dense; D, extremely dense. b)The analysis excluded one case without enhancement.
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Patient age, the presence of symptoms, and mammographic density 
were compared between the two groups. Lesion size on MR 
imaging, signal intensity on T2-weighted images, signal intensity 
on STIR T2-weighted images, internal enhancement on the second 
contrast enhancement, early and delayed enhancement patterns, 
peak enhancement, and ADC values were also compared between 
the two groups. 
The chi-square test and the Fisher exact test were used for 
categorical variables and the Mann-Whitney U test was used for 
continuous variables. All results were analyzed using SPSS version 
20.0 (IBM Corp., Armonk, NY, USA) and P-values of <0.05 were 
considered to indicate statistical significance. 
Results
Of the 33 patients with PMBC, 11 (33.3%) were classified into 
the hypoechogenic group and 22 (66.7%) into the isoechogenic 
to hyperechogenic group. The median age of the patients in the 
hypoechogenic group was 58 years; this value was notably higher 
than the corresponding figure of 46 years in the isoechogenic to 
hyperechogenic group, although this difference was not statistically 
significant (P=0.069) (Table 1). The presence of symptoms and 
A B
Fig. 1. A 75-year-old woman confirmed to have pure mucinous carcinoma of the right breast. 
A. Ultrasonography of the area with a palpable lump in the right breast shows a 13-mm hypoechoic mass. B, C. The mass shows isointensity 
on T2-weighted images (arrow, B) and high internal enhancement on the second subtraction images (arrow, C). D. A low-power view 
visualizes the large lakes of extracellular mucin and clusters of tumor cells (H&E, ×10). 
C D
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mammographic density were not significantly different between the 
two groups (P>0.990 and P=0.121, respectively). Of 33 PMBCs, 
27 (81.8%) and 29 (87.9%) showed high signal intensity on T2-
weighted images and on STIR T2-weighted images, respectively. 
The PMBCs in the isoechogenic to hyperechogenic group were 
significantly more likely to show high signal intensity on T2-
weighted images (21 of 22, 95.5%) than the hypoechogenic group 
(six of 11, 54.5%) (P=0.010) (Figs. 1, 2). On STIR T2-weighted 
images, 95.5% of the PMBCs in the isoechogenic to hyperechogenic 
group (21 of 22) showed a high signal intensity, in contrast to 
72.7% in the hypoechogenic group (eight of 11), but this trend did 
not show statistical significance (P=0.097). Internal enhancement, 
early and delayed enhancement patterns, peak enhancement, and 
mean ADC values did not exhibit significant differences between the 
two groups (P=0.219, P=0.593, P=0.053, P=0.166, and P=0.133, 
respectively). 
None of the 33 patients with PMBC had lymph node metastasis. 
Lesion size on pathology, tumor margin, nuclear and histologic 
grades, and lymphovascular invasion were not significantly different 
between the two groups (P=0.778, P>0.990, P=0.538, P=0.121, 
and P>0.990) (Table 2). All mucinous carcinomas showed ER 
positivity. PR positivity was not significantly different between the 
A B
Fig. 2. A 44-year-old woman confirmed to have pure mucinous carcinoma of the left breast.
A. Ultrasonography of the area with a palpable lump in the left breast shows a 27-mm hyperechoic mass. B, C. The mass shows high signal 
intensity on T2-weighted images (arrow, B) and no internal enhancement on the second subtraction images (arrowheads, C). D. A low-power 
view visualizes small islands of tumor cells within lakes of extracellular mucin (H&E, ×100).
C D
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their internal echogenicity on US.
In the hypoechogenic  group and the isoechogenic  to 
hyperechogenic group, 82% and 88% of PMBCs showed high 
signal intensity on T2- and STIR T2-weighted images in our study, 
respectively, which is comparable to previously reported findings 
of 82% to 100% for T2-weighted images [12,13,21] and 67% to 
100% for STIR T2-weighted images [11,14]. The large amount of 
extracellular mucus, which is rich in free water, in PMBCs is thought 
to contribute to their high signal intensity on T2-weighted and STIR 
T2-weighted MR images [11,12,21]. PMBCs with isoechogenicity 
or hyperechogenicity showed high signal intensity on T2-weighted 
images more frequently than those with hypoechogenicity. This 
two groups (P=0.304). Only one tumor was positive for HER2 in the 
hypoechogenic group and none were positive in the isoechogenic 
to hyperechogenic group (P=0.312). No significant differences were 
observed between the two groups when the cut-off value of ≥14% 
was adopted for Ki-67 proliferation. 
Discussion
PMBCs with isoechogenicity or hyperechogenicity were significantly 
more likely to show high signal intensity on T2-weighted images 
than PMBCs that exhibited hypoechogenicity. The histopathologic 
characteristics of PMBCs did not significantly differ according to 
Table 2. Histopathologic characteristics of mucinous carcinoma according to echogenicity on US
US echogenicity Total Hypoechogenic (n=11) Isoechogenic to hyperechogenic (n=22) P-value
Lesion size (mm) 20 (3-40) 20 (3-38) 19 (8-40) 0.778
Margin >0.990
Expanding 22 (66.7) 7 (63.6) 15 (68.2)
Infiltrative 11 (33.3) 4 (36.4) 7 (31.8)
Nuclear grade 0.538
1 16 (48.5) 4 (36.4) 12 (54.5)
2 17 (51.5) 7 (63.6) 10 (45.5)
Histologic grade 0.121
1 24 (72.7) 6 (54.5) 18 (81.8)
2 9 (27.3) 5 (45.5) 4 (18.2)
Lymph node metastasis
Absence 33 (100) 11 (100) 22 (100)
Lymphovascular invasion >0.990
Absence 31 (93.9) 10 (90.9) 21 (95.5)
Presence 2 (6.1) 1 (9.1) 1 (4.5)
ER
Positive 33 (100) 11 (100) 22 (100)
PR 0.304
Positive 28 (84.8) 8 (72.7) 20 (90.9)
Negative 5 (15.2) 3 (27.3) 2 (9.1)
HER2a) 0.312
Positive 1 (3.1) 1 (10) 0 (
Negative 31 (96.9) 9 (90) 22 (100)
Ki-67b)
Median (range) 5 (1-20) 7 (2-20) 5 (1-20) 0.606
Positive (≥14%) 5 (15.6) 3 (27.3) 2 (9.5) 0.310
Negative (<14%) 27 (84.4) 8 (72.7) 19 (90.5)
Values are presented as median (range) or number (%).
US, ultrasonography; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a)The analysis excluded one case with hypoechogenicity that had a 2+ HER2 immunohistochemistry result, but for which an additional silver-enhanced in situ hybridization 
analysis was not performed. b)The analysis excluded one case with hyperechogenicity for which a Ki-67 assay was not performed. 
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is most likely because PMBCs with hypoechogenicity have more 
hypercellularity and less extracellular mucin. On STIR T2-weighted 
images, 72.7% of PMBCs in the hypoechogenic group showed a 
high signal intensity, in contrast to 54.5% of hypoechogenic PMBCs 
on T2-weighted images. STIR sequences increase the relative signal 
intensity of water content as a result of the additive T1 and T2 
contrast effect, and this results in a notable contrast between water 
content and other tissues [22]. The increased contrast between 
mucin and the background parenchymal tissue might be the reason 
for this difference. 
The mean ADC values were not significantly different between the 
two groups (1.90×10-3 mm²/sec vs. 1.92×10-3 mm²/sec, P=0.133), 
similar to the ADC value of 1.99×10-3 mm²/sec in a previous study 
[14]. This might be because the number of PMBCs included in our 
study was small, and the relative hypercellularity of PMBC with 
hypoechogenicity might not have been a strong enough trend to 
cause a significant difference in ADC values. 
Our results showed that 62.5% of our sample of PMBCs exhibited 
persistent or plateau enhancement pattern in the delayed phase, 
while 37.5% showed a washout pattern. Delayed enhancement 
patterns were substantially different between the two groups. Of the 
PMBCs with hypoechogenicity, 63.6% showed a washout pattern 
on the delayed phase, substantially more than the corresponding 
value of 23.8% of PMBCs with isoechogenicity or hyperechogenicity. 
This difference in the delayed enhancement pattern probably 
occurred because the abundant mucin delays the diffusion of 
contrast medium throughout the stroma and around the epithelial 
component [1,12]. Internal enhancement was not significantly 
different between the two groups. Of the PMBCs, 54.5% and 
9.1% showed isoenhancement and low internal enhancement, 
respectively, which is consistent with previous studies that found 
58.8% of PMBCs to show mild enhancement and 5.9% to be 
without enhancement [13]. 
The pathological characteristics were not significantly different 
between the 2 groups. All PMBCs had nuclear and histologic grades 
of 1 or 2, corresponding to previous results showing 89% and 
100% of PMBCs to be grade 1 or 2 [1,23]. None of the PMBCs 
exhibited lymph node metastasis, in contrast to previous studies 
that reported 0%-16.7% of PMBCs to have lymph node metastasis 
[1,5,6,8,23-25]. Our study found lymphovascular invasion in 6.1% 
of PMBCs, similar to the values of 5.7%-10.3% that have been 
reported in other studies [23,24]. PMBCs are slow-growing and 
are known to have a favorable prognosis due to the presence of 
mucin lakes, which are not vascularized and can slow tumor growth 
[1]. Although, hypocellular breast tumors have a more favorable 
prognosis [26], the relative hypercellularity of PMBCs in the 
hypoechogenic group did not lead to significant differences in the 
pathologic characteristics.
No statistically significant differences in immunohistochemical 
staining were found between the two groups. All PMBCs were 
positive for ER, and 84.8% were positive for PR, comparable with 
previously reported rates of 91%-100% for ER-positivity and 79%-
85.7% for PR-positivity [23,24,27]. Only 3.1% of PMBCs showed 
HER2-positivity in the hypoechogenic group, which is comparable to 
previous reports of 2.9%-7.7% for HER2 expression [23,24]. Of the 
PMBCs, 84.4% were negative for Ki-67 expression when <14% was 
chosen as the cut-off value, which is comparable to the results of a 
previous study in which most PMBCs showed low Ki-67 proliferation 
[24]. 
Our study had several limitations. First, this study had a 
retrospective design and a small number of cases were included. 
Selection bias may have been present. Second, we did not consider 
menstrual status, which can influence the signal intensity of the 
background breast parenchyma. 
In conclusion, PMBCs with isoechogenicity or hyperechogenicity 
were more likely to have a high signal intensity on T2-weighted 
images than PMBCs that exhibited hypoechogenicity. However, the 
pathological characteristics were not significantly different between 
PMBCs exhibiting isoechogenicity or hyperechogenicity and those 
that displayed hypoechogenicity.
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